PF-06817024 / Pfizer - LARVOL DELTA

Optimizing Biologic Treatment Selection in Chronic Rhinosinusitis with Nasal Polyps: A Network Meta-Analysis of Efficacy and Safety Across 22 RCTs. (PubMed, Pharmaceuticals (Basel)) - "PF-06817024 ranked best in minimizing any adverse events and serious adverse events. The placebo ranked worst across nearly all endpoints. Dupilumab, CM31 0, and Tezepelumab exhibit the most favorable efficacy profiles across multiple CRSwNP domains, while all drugs show a nearly similar safety profile."

Journal • Retrospective data • Review • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Exploratory pharmacodynamics and efficacy of PF-06817024 in a Phase 1 study of patients with chronic rhinosinusitis and atopic dermatitis. (PubMed, Allergy Asthma Clin Immunol) - P1 | "Trial registration ClinicalTrials.gov, NCT02743871. Registered 15 April 2016, https://clinicaltrials.gov/study/NCT02743871?term=NCT02743871&rank=1 ."

Journal • P1 data • PK/PD data • Allergy • Atopic Dermatitis • Chronic Rhinosinusitis With Nasal Polyps • Dermatitis • Dermatology • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Pruritus • Respiratory Diseases • Sinusitis • IL33

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06817024 in Healthy Participants, Participants With Chronic Rhinosinusitis With Nasal Polyps, and Participants With Atopic Dermatitis: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study. (PubMed, J Clin Pharmacol) - "In addition, dose-dependent increases were observed in total serum IL-33 levels of treated participants, indicating target engagement. Overall, the PK and safety profile of PF-06817024 supports further investigation of the drug as a potential treatment for allergic diseases."

Clinical • Journal • P1 data • PK/PD data • Allergy • Atopic Dermatitis • Chronic Rhinosinusitis With Nasal Polyps • Dermatitis • Dermatology • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis • IL33

Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis (clinicaltrials.gov) - P1; N=98; Completed; Sponsor: Pfizer; Active, not recruiting ➔ Completed

Trial completion • Atopic Dermatitis • Chronic Rhinosinusitis With Nasal Polyps • Dermatitis • Dermatology • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis